HEICO (NYSE:HEI) Q1 2026 Earnings call February 26, 2026 09:00 AM ET Company ParticipantsCarlos Macau - Executive Vice President, Chief Financial Officer, and TreasurerEric Mendelson - Co-Chairman of the Board and Co-Chief Executive OfficerJonathan Siegmann - Managing Director, Equity ResearchLouis Raffetto - Senior Vice President, Equity ResearchMax Miller - Equity Research Associate, Aerospace and DefenseScott Mikus - Vice President, Equity ResearchSheila Kahyaoglu - Managing Director, Equity ResearchVict ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Picard Medical To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Picard Medical between September 2, 2025 and October 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. ...

Key Takeaways Pediatrix Medical Group's Q4 EPS of 50 cents missed estimates as revenues fell 1.7% year over year.MD saw 4% same-unit revenue growth, driven by 6.7% gains in reimbursement-related factors.MD sees 2026 EBITDA outlook at $280-$300M and repurchased 4.1M shares in 2025.Pediatrix Medical Group, Inc. (MD) reported fourth-quarter 2025 adjusted earnings per share (EPS) of 50 cents, which missed the Zacks Consensus Estimate by 4.9%. The bottom line declined 2% year over year.Net revenues decreased 1.7 ...

Core Insights - Exact Sciences Corporation (EXAS) reported a net loss of 21 cents per share in Q4 2025, which is higher than the loss of 6 cents in the same quarter last year, aligning with the Zacks Consensus Estimate [1] - For the full year 2025, earnings per share were 7 cents, a significant improvement from the loss of 23 cents in the previous year [1] EXAS Revenues - Q4 consolidated revenues reached $878.4 million, reflecting a 23.1% increase on a reported basis and 23% on a core revenue basis, surpassing the Zacks Consensus Estimate by 2.1% [2] - Full-year 2025 consolidated revenues totaled $3.25 billion, marking a 17.7% increase on a reported basis and 18% on a core revenue basis [2] - Following the earnings announcement, EXAS shares saw a slight increase of 0.07% [2] EXAS Q4 Segments in Detail - Screening revenues, which include laboratory service revenues from Cologuard and PreventionGenetics, amounted to $695.1 million, up 26% year over year [3] - Precision Oncology revenues, including laboratory service revenues from global Oncotype products and therapy selection products, were $183.2 million, reflecting a 14% year-over-year increase and 12% on a core basis [3] EXAS' Margins - Gross profit increased by 25% year over year to $615.8 million, with gross margin expanding by 106 basis points to 70.1% [4] - Research and development expenses rose by 96% year over year to $191.5 million, while sales and marketing expenses increased by 18% to $288.5 million [4] - General and administrative expenses grew by 14.1% year over year to $218 million [4] EXAS' Financial Update - At the end of Q4 2025, Exact Sciences had cash and cash equivalents and marketable securities totaling $964.7 million, down from $1.04 billion at the end of Q4 2024 [6] - Cumulative net cash provided by operating activities was $491.4 million, compared to $210.5 million in the previous year [6] Notable Developments - In Q4, Exact Sciences announced the first clinical study results from its Oncodetect molecular residual disease test in breast cancer, which showed favorable outcomes [10] - The company also reported pivotal clinical validation results from the ALTUS study during the quarter [10] - On November 19, 2025, Exact Sciences entered into a merger agreement with Abbott Laboratories, aiming for a close in Q2 2026, pending regulatory approvals [11]

Elon Musk Keeps Telling People To Use AI For Medical Advice—But Grok Says Not Tohttps://t.co/gcfCar9xpi https://t.co/3x7ykdNQve ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Picard Medical, Inc. due to allegations of securities law violations, including misleading statements and undisclosed fraudulent activities [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses in Picard Medical between September 2, 2025, and October 31, 2025, to discuss their legal options [1]. - There is a deadline of April 13, 2026, for investors to seek the role of lead plaintiff in a federal securities class action against Picard Medical [2]. - The complaint alleges that Picard Medical and its executives made false statements and failed to disclose involvement in a fraudulent stock promotion scheme [4]. Group 2: Stock Performance and Impact - On October 24, 2025, Picard Medical's shares closed at $5.31, a significant drop from $13.20 on October 23, 2025, representing a decline of $7.89 per share or approximately 59.8% in a single trading session [5]. - This decline marks one of the most significant one-day drops since the company's recent IPO [5]. Group 3: Firm Background and Support - Faruqi & Faruqi, LLP has recovered hundreds of millions of dollars for investors since its founding in 1995 and has offices in New York, Pennsylvania, California, and Georgia [3]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Picard Medical's conduct [7].

Core Viewpoint - A class action securities lawsuit has been filed against Picard Medical, Inc. for alleged securities fraud affecting investors between September 2, 2025, and October 31, 2025 [1][2] Group 1: Allegations of Fraud - The lawsuit claims that Picard Medical was involved in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [2] - It is alleged that insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [2] - The company's public statements and risk disclosures reportedly omitted any mention of false rumors and artificial trading activity that influenced the stock price [2] - As a result, the positive statements made by the defendants regarding the company's business, operations, and prospects were materially misleading and lacked a reasonable basis [2] Group 2: Legal Process and Participation - Investors who suffered losses in Picard Medical during the specified timeframe have until April 3, 2026, to request to be appointed as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, and participation does not require serving as a lead plaintiff [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has a strong track record in high-stakes securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Group 1 - The article highlights the upcoming deadline of February 17, 2026, for investors to file a lead plaintiff motion in a case concerning Charming Medical Limited (NASDAQ: MCTA) [1] - The case is filed on behalf of investors who purchased Charming Medical Limited securities during the class period from October 10, 2025, to November 12, 2025 [1] - Investors who suffered losses in Charming Medical Limited are encouraged to contact the Law Offices of Howard G. Smith for assistance [1]

Group 1 - The article discusses a class action lawsuit against Charming Medical Limited (MCTA) for securities fraud, with a deadline for shareholders to file a lead plaintiff motion by February 17, 2026 [1] - The lawsuit claims that during the class period from October 10, 2025, to November 12, 2025, the company made materially false and misleading statements regarding its business and operations [1] - The SEC halted trading of Charming securities on November 11, 2025, due to potential manipulation through social media recommendations aimed at artificially inflating the stock price [1] Group 2 - Allegations in the lawsuit include that insiders used offshore accounts to facilitate the dumping of shares during a price inflation campaign, and that the company failed to disclose material adverse facts [1] - The complaint asserts that the company's public statements omitted any mention of false rumors and artificial trading activity that influenced the stock price [1] - Shareholders who acquired Charming securities during the class period are encouraged to participate in the lawsuit to recover losses under federal securities laws [1]

Core Viewpoint - A class action lawsuit has been filed against Picard Medical, Inc. for allegedly issuing false and misleading statements during a specific class period from September 2, 2025, to October 31, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities that purchased or acquired Picard shares during the class period [1] - Investors have until April 3, 2026, to seek appointments as lead plaintiff [1][2] Group 2: Allegations Against Picard Medical - The complaint alleges that Picard Medical was involved in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [6] - Insiders and/or affiliates reportedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [6] - Picard's public statements and risk disclosures allegedly omitted any mention of false rumors and artificial trading activity that influenced the stock price [6]